Novartis Ag Adr Stock Today
| NVS Stock | USD 110.66 2.83 2.49% |
PerformanceOK
| Odds Of DistressLow
|
Novartis is selling for under 110.66 as of the 1st of May 2025; that is 2.49% down since the beginning of the trading day. The stock's lowest day price was 110.66. Novartis has only a 8 % chance of going through financial distress over the next few years but had a somewhat ok performance during the last 90 days. Note, on November 25, 2021, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Novartis AG ADR's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of June 2026 | Category Healthcare | Classification Health Care |
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 1.98 B outstanding shares of which 4.51 M shares are now shorted by investors with about 1.48 days to cover. More on Novartis AG ADR
Moving against Novartis Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Novartis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Richard Saynor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Compulsion, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNovartis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novartis' financial leverage. It provides some insight into what part of Novartis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis AG ADR (NVS) is traded on New York Stock Exchange in USA. It is located in Lichtstrasse 35, Basel, Switzerland, 4056 and employs 75,883 people. Novartis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 226.55 B. Novartis AG ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 1.98 B outstanding shares of which 4.51 M shares are now shorted by investors with about 1.48 days to cover.
Novartis AG ADR has about 4.64 B in cash with 17.62 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.84.
Check Novartis Probability Of Bankruptcy
Ownership AllocationRoughly 94.0 % of Novartis outstanding shares are held by general public with 6.0 % by institutional investors. Please note that on November 25, 2021, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Novartis AG ADR's common stock.
Check Novartis Ownership Details
Novartis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2021-11-18 | 2.3 M | |
| Cullen Capital Management, Llc | 2021-11-18 | 2.2 M | |
| Northern Trust Corp | 2021-11-18 | 2.1 M | |
| Fisher Asset Management, Llc | 2021-11-18 | 2 M | |
| Blackrock Inc | 2021-11-18 | 2 M | |
| Envestnet Asset Management Inc | 2021-11-18 | 1.9 M | |
| Wells Fargo & Co | 2021-11-18 | 1.9 M | |
| Ubs Group Ag | 2021-11-18 | 1.7 M | |
| State Street Corp | 2021-11-18 | 1.6 M | |
| Dodge & Cox | 2021-11-18 | 12.2 M | |
| Primecap Management Company | 2021-11-18 | 11 M |
Novartis Historical Income Statement
Novartis Stock Against Markets
Novartis Corporate Directors
| Ton Buechner | Non-Executive Independent Director | Profile | |
| Frans Houten | Non-Executive Independent Director | Profile | |
| Nancy Andrews | Non-Executive Independent Director | Profile | |
| Elizabeth Doherty | Non-Executive Independent Director | Profile |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.